How is the Thyroid Gland Doing After COVID-19 Infection?
New research shows that there is a clear link between thyroid dysfunction and COVID-19 disease through various mechanisms.
Source: medindia.net
About Thyroid News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from About Thyroid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In About Thyroid Today - Breaking & Trending Today
Exelixis, Inc.: Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
- Approval is based on COSMIC-311 trial, in which CABOMETYX demonstrated significant improvement in progression-free survival versus placebo - Exelixis, Inc. (Nasdaq: EXEL) today announced that
Source: finanznachrichten.de
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
– CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – ... | March 25, 2022
Source: marketscreener.com
Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer
Published: Dec 21, 2020 ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 ...
Source: biospace.com